Medical Device Network on MSN
FDA clears Insulet’s Omnipod 5 algorithm enhancements
Insulet anticipates that the Omnipod 5 algorithm update will launch in the US in H1 2026. The company highlighted that the ...
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its ...
Insulet (PODD) announced it has received FDA 510(k) clearance for significant enhancements to the Omnipod 5 Automated Insulin Delivery System.
The medtech firm plans to launch its next flagship patch-pump in 2027, and its first fully closed loop system for Type 2 ...
Insulin pump-maker Insulet has scored FDA 510(k) clearance for its Omnipod 5 Automated Insulin Delivery System for people ages 6 and up with Type 1 diabetes. The pump integrates with the Dexcom G6 ...
ACTON, Mass., June 26, 2021--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, ...
Insulet Corporation delivers strong fundamentals, with robust revenue growth, high margins, and impressive ROC. Learn more ...
Insulet Corporation PODD recently received CE mark approval under the European Medical Device Regulation for the added compatibility of the Abbott Laboratories’ ABT FreeStyle Libre 2 Plus sensor with ...
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented ...
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback